MHRA reissues LABA advice

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a reminder to prescribers on the use of long-acting ß2 agonists.

LABAs are indicated for long-term use and not to relieve acute asthma symptoms.
LABAs are indicated for long-term use and not to relieve acute asthma symptoms.

The advice is consistent with the guidelines issued by the British Thoracic Society and Scottish Intercollegiate Guidelines Network. It reminds prescribers:

  • To prescribe long-acting β2 agonists (LABAs) only with inhaled corticosteroids (ICS) and when ICS alone fail to control asthma symptoms.
  • Not to initiate LABA treatment in patients with rapidly deteriorating asthma.
  • To use the lowest effective dose, review treatment regularly, and discontinue if there is no benefit.
  • To consider stepping-down when good long-term asthma control is achieved.
  • Not to prescribe LABA for exercise-induced asthma without regular ICS (a short-acting β2-agonist should be used instead).
  • To prescribe combination inhalers when appropriate.

See the MIMS summary of BTS/SIGN asthma guidelines for more information.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases